|
KMID : 1149120220190020057
|
|
Journal of the Korean Society for Psoriasis
2022 Volume.19 No. 2 p.57 ~ p.60
|
|
|
A Case of Lung Cancer Diagnosed during Secukinumab Treatment in a Patient with Psoriasis
|
|
Shim Dong-Hyun
Jeong Byung-Hoon
Choi Hoon
Kim Min-Sung
Na Chan-Ho
|
|
|
Abstract
|
|
|
|
Psoriasis is a chronic inflammatory skin disease that affects the health and quality of life of patients. Biologics including interleukin-17A inhibitors have shown good efficacy and tolerable safety in patients with moderate-to-severe psoriasis. A 58-year-old man presented with mild pruritic multiple papules and plaques with scales on his whole body for more than 30 years. The patient diagnosed with psoriasis had been treated with phototherapy for more than 3 months, but the skin symptoms were rather aggravated, so secukinumab treatment was introduced. The patient’s skin lesions improved rapidly, and secukinumab treatment was continued without any adverse events for several years. However, 62 months later, the patient informed that he was diagnosed with lung cancer and had undergone surgery. Since then, the patient discontinued secukinumab treatment and has been treated with topical agents. Herein, we report a case of lung cancer diagnosed during secukinumab treatment in a patient with psoriasis.
|
|
|
KEYWORD
|
|
|
Biologics, Malignancy, Psoriasis, Secukinumab
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|